Unraveling complexity. Harnessing insights.
Celcuity Inc. is a publicly listed (NASDAQ: CELC) clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy. Our mission is to extend the lives of cancer patients by leveraging our proprietary CELsignia platform to develop first-in-class therapies and companion diagnostics.
Celcuity’s lead therapeutic candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTOR inhibitor. Celcuity is currently planning to initiate a Phase 3 registration-enabling clinical trial to evaluate gedatolisib as a potential first-in-class treatment for patients with ER+/HER2-negative metastatic breast cancer. Our CELsignia companion diagnostics are currently being evaluated in five clinical trials to assess whether breast cancer patients identified with a CELsignia test respond to a matching targeted therapy.
Data Provided by Quotemedia with delay
There are currently no events to display.
Event Title
May 16, 2022 at 4:30 PM ET
Celcuity First Quarter 2022 Financial Results Webcast/Conference Call
March 23, 2022 at 4:30 PM ET
Celcuity Fourth Quarter and Full Year 2021 Financial Results Conference Call
April 14, 2022 at 11:00 AM ET
Canaccord Genuity Horizons in Oncology Conference
We are a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. CELsignia is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies.